Conclusions. In the absence of comparative data, the evidence is insufficient to permit conclusions on the comparative effectiveness of these therapies for unresectable CRC metastases to the liver. Gaps in the research base, even for critical benefits or harms, are extensive, and the quality of studies is generally questionable. Conducting RCTs (ideally head-to-head comparisons) to answer many important questions is desirable, but challenging.